Enanta Pharmaceuticals Inc (ENTA)

[willyw]

Is it possible that Abbvie 3D may be approved for some indications for only 12 weeks where Gilead is labeled for 24 weeks (in cirrhotic past failures)?
I'm not asking if it is a shoo in, but possible?

I've started on a much lengthier post supporting that proposition, I wonder if genotype 1B past treatment failure cirrhotic may/will only need 12 weeks with RBV based on trials in the 3D program?

http://www.natap.org/2014/EASL/EASL_27.htm

What would the pricing ramifications of Abbvie 12 weeks versus Gilead 24 weeks on these respective groups? Would this not affect the number of prescriptions written on certain past failure cirrhotic groups, skewing them from Gilead to Abbvie?

Also, was the Gilead 24 week treatment duration wholly expected? If it was not, would this not be bullish for ENTA?

I have to plead ignorance on the SVR results of the Gilead cirrhotics and cirrhotic sub groups. I have not found any good breakdown on response and SVR rates for cirrhotics.
Wondering why? : )

I wonder if the larger more comprehensive Abbvie trials may mean better approval outcomes.

Thoughts?